{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:15:26Z","timestamp":1791317726125,"version":"4.3.1"},"reference-count":230,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:00:00Z","timestamp":1721174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Res &amp; Perspec"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Obesity, a global health challenge, necessitates innovative approaches for effective management. Targeting gut peptides in the development of anti\u2010obesity pharmaceuticals has already demonstrated significant efficacy. Ghrelin, peptide YY (PYY), cholecystokinin (CCK), and amylin are crucial in appetite regulation offering promising targets for pharmacological interventions in obesity treatment using both peptide\u2010based and small molecule\u2010based pharmaceuticals. Ghrelin, a sole orexigenic gut peptide, has a potential for anti\u2010obesity therapies through various approaches, including endogenous ghrelin neutralization, ghrelin receptor antagonists, ghrelin O\u2010acyltransferase, and functional inhibitors. Anorexigenic gut peptides, peptide YY, cholecystokinin, and amylin, have exhibited appetite\u2010reducing effects in animal models and humans. Overcoming substantial obstacles is imperative for translating these findings into clinically effective pharmaceuticals. Peptide YY and cholecystokinin analogues, characterized by prolonged half\u2010life and resistance to proteolytic enzymes, present viable options. Positive allosteric modulators emerge as a novel approach for modulating the cholecystokinin pathway. Amylin is currently the most promising, with both amylin analogues and dual amylin and calcitonin receptor agonists (DACRAs) progressing to advanced stages of clinical trials. Despite persistent challenges, innovative pharmaceutical strategies provide a glimpse into the future of anti\u2010obesity therapies.<\/jats:p>","DOI":"10.1002\/prp2.1243","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T09:30:59Z","timestamp":1721208659000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Novel Pharmaceuticals in Appetite Regulation: Exploring emerging gut peptides and their pharmacological prospects"],"prefix":"10.1002","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1640-1421","authenticated-orcid":false,"given":"Igor","family":"Rubini\u0107","sequence":"first","affiliation":[{"name":"Department of Basic and Clinical Pharmacology and Toxicology, Faculty of Medicine University of Rijeka  Rijeka Croatia"},{"name":"Clinical Pharmacology unit Clinical Hospital Center Rijeka  Rijeka Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3385-0867","authenticated-orcid":false,"given":"Marija","family":"Kurtov","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology and Toxicology, Department of Internal Medicine University Hospital \u201cSveti Duh\u201d  Zagreb Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1413-4862","authenticated-orcid":false,"given":"Robert","family":"Liki\u0107","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine School of Medicine University of Zagreb  Zagreb Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,7,17]]},"reference":[{"key":"e_1_2_17_2_1","unstructured":"World Health Organization.Obesity. Accessed November 7 2023.https:\/\/www.who.int\/health\u2010topics\/obesity#tab=tab_1"},{"key":"e_1_2_17_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2017.02.104"},{"key":"e_1_2_17_4_1","doi-asserted-by":"publisher","DOI":"10.1159\/000492115"},{"key":"e_1_2_17_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcx152"},{"key":"e_1_2_17_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101850"},{"key":"e_1_2_17_7_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2021.20410"},{"key":"e_1_2_17_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-021-01358-1"},{"key":"e_1_2_17_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2022.2053676"},{"key":"e_1_2_17_10_1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2023-0168"},{"key":"e_1_2_17_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.706978"},{"key":"e_1_2_17_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/nu13020481"},{"key":"e_1_2_17_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx1121"},{"key":"e_1_2_17_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.16177"},{"key":"e_1_2_17_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13679-015-0184-5"},{"key":"e_1_2_17_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/lifemeta\/loac002"},{"key":"e_1_2_17_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2021.101794"},{"key":"e_1_2_17_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.21770"},{"key":"e_1_2_17_19_1","doi-asserted-by":"publisher","DOI":"10.1210\/er.2006-0028"},{"key":"e_1_2_17_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-29678-2_3931"},{"key":"e_1_2_17_21_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2017.281568"},{"key":"e_1_2_17_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/87551225221116010"},{"key":"e_1_2_17_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-0897-4_9"},{"key":"e_1_2_17_24_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00021.2017"},{"key":"e_1_2_17_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2010.132"},{"key":"e_1_2_17_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101882"},{"key":"e_1_2_17_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00337-8"},{"key":"e_1_2_17_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.838410"},{"key":"e_1_2_17_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13433"},{"key":"e_1_2_17_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/cphy.c180013"},{"key":"e_1_2_17_31_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1085799"},{"key":"e_1_2_17_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61267-7"},{"key":"e_1_2_17_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31773-2"},{"key":"e_1_2_17_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411892"},{"key":"e_1_2_17_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2013.120"},{"key":"e_1_2_17_36_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1132004"},{"key":"e_1_2_17_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2016.03.005"},{"key":"e_1_2_17_38_1","doi-asserted-by":"publisher","DOI":"10.1210\/endo.136.8.7628397"},{"key":"e_1_2_17_39_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.53.3.654"},{"key":"e_1_2_17_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm727"},{"key":"e_1_2_17_41_1","doi-asserted-by":"publisher","DOI":"10.2337\/dbi21-0001"},{"key":"e_1_2_17_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2018.12.001"},{"key":"e_1_2_17_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101139"},{"key":"e_1_2_17_44_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107519"},{"key":"e_1_2_17_45_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0078"},{"key":"e_1_2_17_46_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0285197"},{"key":"e_1_2_17_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2018.09.009"},{"key":"e_1_2_17_48_1","unstructured":"Food and Drug Administration.Orlistat (marketed as Alli and Xenical) Information.2015Accessed November 7 2023.https:\/\/www.fda.gov\/drugs\/postmarket\u2010drug\u2010safety\u2010information\u2010patients\u2010and\u2010providers\/orlistat\u2010marketed\u2010alli\u2010and\u2010xenical\u2010information"},{"key":"e_1_2_17_49_1","unstructured":"European medicines agency.Xenical.2023Accessed November 7 2023.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xenical"},{"key":"e_1_2_17_50_1","unstructured":"VIVUS Inc.Qsymia: Highlights of Prescribing Information.2012Accessed November 7 2023.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/022580s000lbl.pdf"},{"key":"e_1_2_17_51_1","unstructured":"European Medicines Agency.Qsiva.2013Accessed November 7 2023.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/qsiva"},{"key":"e_1_2_17_52_1","unstructured":"Orexigen Therapeutics Inc.Contrave: Highlights of Prescribing Information.2014Accessed November 7 2023.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/200063s000lbl.pdf"},{"key":"e_1_2_17_53_1","unstructured":"European Medicines Agency.Mysimba.2023Accessed November 7 2023.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mysimba"},{"key":"e_1_2_17_54_1","unstructured":"European Medicines Agency.Saxenda.2023Accessed November 7 2023.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/saxenda"},{"key":"e_1_2_17_55_1","unstructured":"Novo Nordisk.Saxenda: Highlights of Prescribing Information.2014Accessed November 7 2023.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206321orig1s000lbl.pdf"},{"key":"e_1_2_17_56_1","unstructured":"Food and Drug Administration.FDA approves weight management drug for patients aged 12 and older.2020Accessed December 9 2023.https:\/\/www.fda.gov\/drugs\/news\u2010events\u2010human\u2010drugs\/fda\u2010approves\u2010weight\u2010management\u2010drug\u2010patients\u2010aged\u201012\u2010and\u2010older"},{"key":"e_1_2_17_57_1","unstructured":"Novo Nordisk.Wegovy: Highlights of Prescribing Information.2022Accessed November 7 2023.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/215256s007lbl.pdf"},{"key":"e_1_2_17_58_1","unstructured":"European Medicines Agency.Wegovy.2023Accessed November 7 2023.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/wegovy"},{"key":"e_1_2_17_59_1","unstructured":"Eli Lilly and Company.Zepbound: Highlights of Prescribing Information.2023Accessed November 7 2023.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217806s000lbl.pdf"},{"key":"e_1_2_17_60_1","unstructured":"European Medicines Agency.Mounjaro\u2014opinion on variation to marketing authorisation.2023Accessed December 7 2023."},{"key":"e_1_2_17_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/45230"},{"key":"e_1_2_17_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/35038090"},{"key":"e_1_2_17_63_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.12.8111"},{"key":"e_1_2_17_64_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.50.4.707"},{"key":"e_1_2_17_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2008.01.017"},{"key":"e_1_2_17_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2015.03.005"},{"key":"e_1_2_17_67_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v25.i5.539"},{"key":"e_1_2_17_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0083-6729(06)77002-9"},{"key":"e_1_2_17_69_1","article-title":"Biochemistry, ghrelin","author":"Young E","year":"2023","journal-title":"StatPearls"},{"key":"e_1_2_17_70_1","doi-asserted-by":"publisher","DOI":"10.1152\/physiol.00024.2021"},{"key":"e_1_2_17_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.02.008"},{"key":"e_1_2_17_72_1","doi-asserted-by":"publisher","DOI":"10.1111\/jne.12728"},{"key":"e_1_2_17_73_1","doi-asserted-by":"publisher","DOI":"10.3390\/nu14194191"},{"key":"e_1_2_17_74_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2019-00056"},{"key":"e_1_2_17_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2008.03.007"},{"key":"e_1_2_17_76_1","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.113.075291"},{"key":"e_1_2_17_77_1","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/879503"},{"key":"e_1_2_17_78_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043384"},{"key":"e_1_2_17_79_1","doi-asserted-by":"publisher","DOI":"10.1038\/embor.2012.174"},{"key":"e_1_2_17_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101352"},{"key":"e_1_2_17_81_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2552-05.2005"},{"key":"e_1_2_17_82_1","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnab025"},{"key":"e_1_2_17_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.appet.2022.105965"},{"key":"e_1_2_17_84_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.50.8.1714"},{"key":"e_1_2_17_85_1","doi-asserted-by":"publisher","DOI":"10.1007\/164_2016_104"},{"key":"e_1_2_17_86_1","doi-asserted-by":"publisher","DOI":"10.3390\/nu11030493"},{"key":"e_1_2_17_87_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2869.2008.00662.x"},{"key":"e_1_2_17_88_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.23616"},{"key":"e_1_2_17_89_1","doi-asserted-by":"publisher","DOI":"10.3390\/nu13030784"},{"key":"e_1_2_17_90_1","doi-asserted-by":"publisher","DOI":"10.1111\/jne.12693"},{"key":"e_1_2_17_91_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-06636-3"},{"key":"e_1_2_17_92_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389557511313040007"},{"key":"e_1_2_17_93_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c02191"},{"key":"e_1_2_17_94_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18040798"},{"key":"e_1_2_17_95_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10010053"},{"key":"e_1_2_17_96_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1268366"},{"key":"e_1_2_17_97_1","unstructured":"European Medicines Agency.EU\/3\/17\/1882\u2014orphan designation for treatment of growth hormone deficiency.2017Accessed November 7 2023."},{"key":"e_1_2_17_98_1","doi-asserted-by":"publisher","DOI":"10.1097\/SPC.0000000000000658"},{"key":"e_1_2_17_99_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867327666200615152804"},{"key":"e_1_2_17_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100612"},{"key":"e_1_2_17_101_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190849"},{"key":"e_1_2_17_102_1","doi-asserted-by":"publisher","DOI":"10.17925\/EE.2022.18.2.84"},{"key":"e_1_2_17_103_1","doi-asserted-by":"publisher","DOI":"10.2174\/13816128113199990506"},{"key":"e_1_2_17_104_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0605376103"},{"key":"e_1_2_17_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.domaniend.2006.05.005"},{"key":"e_1_2_17_106_1","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2016.137"},{"key":"e_1_2_17_107_1","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S60398"},{"key":"e_1_2_17_108_1","unstructured":"AdisInsight.CYT 009 GhrQb: Drug Profile.2006Accessed November 7 2023.https:\/\/adisinsight.springer.com\/drugs\/800023624#disabled"},{"key":"e_1_2_17_109_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2826.2007.01619.x"},{"key":"e_1_2_17_110_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2009-0003"},{"key":"e_1_2_17_111_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2007-0239"},{"key":"e_1_2_17_112_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.718615"},{"key":"e_1_2_17_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2017.10.016"},{"key":"e_1_2_17_114_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.717544"},{"key":"e_1_2_17_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100582"},{"key":"e_1_2_17_116_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2020.1776263"},{"key":"e_1_2_17_117_1","unstructured":"University College L.BARI\u2010INSIGHT: A Double\u2010Blind Placebo\u2010Controlled Within\u2010Subject Cross\u2010over Mechanistic Study Investigating the Role of Ghrelin in Regulating Appetite and Energy Intake in Patients Following Bariatric Surgery.2020Accessed December 7 2023.https:\/\/clinicaltrials.gov\/study\/NCT03641417"},{"key":"e_1_2_17_118_1","unstructured":"National Institute on Drug Abuse (NIDA).Manipulating Ghrelin Signaling Via GOAT Inhibition in Alcohol Use Disorder.2023https:\/\/clinicaltrials.gov\/study\/NCT03896516"},{"key":"e_1_2_17_119_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac105"},{"key":"e_1_2_17_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2023.155550"},{"key":"e_1_2_17_121_1","unstructured":"Millendo Therapeutics SAS.A Phase 2b\/3 Study to Evaluate the Safety Tolerability and Effects of Livoletide (AZP\u2010531) an Unacylated Ghrelin Analogue on Food\u2010Related Behaviors in Patients With Prader\u2010Willi Syndrome.2021Accessed November 7 2023.https:\/\/clinicaltrials.gov\/study\/NCT03790865"},{"key":"e_1_2_17_122_1","volume-title":"Millendo Discontinues Livoletide Program for PWS","author":"Strong T","year":"2020"},{"key":"e_1_2_17_123_1","doi-asserted-by":"publisher","DOI":"10.17925\/EE.2015.11.02.90"},{"key":"e_1_2_17_124_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.038737"},{"key":"e_1_2_17_125_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.03.048"},{"key":"e_1_2_17_126_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCO.0b013e328365b9be"},{"key":"e_1_2_17_127_1","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.11168"},{"key":"e_1_2_17_128_1","doi-asserted-by":"publisher","DOI":"10.2174\/156802607782340966"},{"key":"e_1_2_17_129_1","doi-asserted-by":"publisher","DOI":"10.1038\/285417a0"},{"key":"e_1_2_17_130_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2017.11.005"},{"key":"e_1_2_17_131_1","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2008.164269"},{"key":"e_1_2_17_132_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2023.106808"},{"key":"e_1_2_17_133_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2017.10.011"},{"key":"e_1_2_17_134_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00080"},{"key":"e_1_2_17_135_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2006.08.001"},{"key":"e_1_2_17_136_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature00887"},{"key":"e_1_2_17_137_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1575-0922(08)72793-1"},{"key":"e_1_2_17_138_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2005-0972"},{"key":"e_1_2_17_139_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-014-3292-y"},{"key":"e_1_2_17_140_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yfrne.2014.12.003"},{"key":"e_1_2_17_141_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13679-020-00396-9"},{"key":"e_1_2_17_142_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-006-0310-8"},{"key":"e_1_2_17_143_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2003.tb03176.x"},{"key":"e_1_2_17_144_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2016.07.020"},{"key":"e_1_2_17_145_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.04.047"},{"key":"e_1_2_17_146_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030204"},{"key":"e_1_2_17_147_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2011.10.001"},{"key":"e_1_2_17_148_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00153.2007"},{"key":"e_1_2_17_149_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-1806"},{"key":"e_1_2_17_150_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-021-03077-x"},{"key":"e_1_2_17_151_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b01046"},{"key":"e_1_2_17_152_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2006.10.007"},{"key":"e_1_2_17_153_1","doi-asserted-by":"publisher","DOI":"10.1002\/psc.1170"},{"key":"e_1_2_17_154_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2019-00100"},{"key":"e_1_2_17_155_1","doi-asserted-by":"publisher","DOI":"10.1530\/endoabs.90.P326"},{"key":"e_1_2_17_156_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2019.01.017"},{"key":"e_1_2_17_157_1","unstructured":"Novo Nordisk A\/S.A Research Study of NNC0165\u20101562 and Semaglutide in People Who Are Overweight or Obese.2021Accessed December 7 2023.https:\/\/clinicaltrials.gov\/study\/NCT03574584"},{"key":"e_1_2_17_158_1","unstructured":"HemmingsenMA.Diabetes fusion tablet and potential obesity drug dropped by Novo Nordisk. MedWatch.2023; Accessed December 7 2023.https:\/\/medwatch.com\/News\/Pharma___Biotech\/article16344607.ece"},{"key":"e_1_2_17_159_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.physiol.59.1.221"},{"key":"e_1_2_17_160_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(02)02330-5"},{"key":"e_1_2_17_161_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2016.12.010"},{"key":"e_1_2_17_162_1","unstructured":"LiddleRA LamontJT GroverS.Physiology of cholecystokinin. UpToDate.2023; Accessed December 7 2023.https:\/\/www.uptodate.com\/contents\/physiology\u2010of\u2010cholecystokinin"},{"key":"e_1_2_17_163_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.684656"},{"key":"e_1_2_17_164_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2017.00047"},{"key":"e_1_2_17_165_1","doi-asserted-by":"publisher","DOI":"10.1530\/JME-20-0134"},{"key":"e_1_2_17_166_1","doi-asserted-by":"publisher","DOI":"10.7570\/jomes22031"},{"key":"e_1_2_17_167_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2020.170492"},{"key":"e_1_2_17_168_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00112"},{"key":"e_1_2_17_169_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2017.09.007"},{"key":"e_1_2_17_170_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph14111185"},{"key":"e_1_2_17_171_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2010-0233"},{"key":"e_1_2_17_172_1","doi-asserted-by":"publisher","DOI":"10.1038\/245323a0"},{"key":"e_1_2_17_173_1","doi-asserted-by":"publisher","DOI":"10.1080\/clb.61.234.19.27"},{"key":"e_1_2_17_174_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2013.04.004"},{"key":"e_1_2_17_175_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-012-2654-6"},{"key":"e_1_2_17_176_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-019-0386-0"},{"key":"e_1_2_17_177_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2008.07.083"},{"key":"e_1_2_17_178_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2008.06.057"},{"key":"e_1_2_17_179_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm950626d"},{"key":"e_1_2_17_180_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100272"},{"key":"e_1_2_17_181_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.789957"},{"key":"e_1_2_17_182_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.slasd.2022.07.001"},{"key":"e_1_2_17_183_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389203720666190328111833"},{"key":"e_1_2_17_184_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.115.010629"},{"key":"e_1_2_17_185_1","doi-asserted-by":"publisher","DOI":"10.7570\/jomes21071"},{"key":"e_1_2_17_186_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.617400"},{"key":"e_1_2_17_187_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2020.170366"},{"key":"e_1_2_17_188_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2011.01717.x"},{"key":"e_1_2_17_189_1","doi-asserted-by":"publisher","DOI":"10.1038\/celldisc.2016.12"},{"key":"e_1_2_17_190_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2017.11.009"},{"key":"e_1_2_17_191_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11082207"},{"key":"e_1_2_17_192_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2016.02.034"},{"key":"e_1_2_17_193_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.1996.271.6.R1654"},{"key":"e_1_2_17_194_1","doi-asserted-by":"publisher","DOI":"10.1016\/0031-9384(95)02067-5"},{"key":"e_1_2_17_195_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2006-0393"},{"key":"e_1_2_17_196_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13496"},{"key":"e_1_2_17_197_1","doi-asserted-by":"publisher","DOI":"10.2337\/db06-0734"},{"key":"e_1_2_17_198_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2005.10.009"},{"key":"e_1_2_17_199_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijpvm.IJPVM_425_20"},{"key":"e_1_2_17_200_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp050341"},{"key":"e_1_2_17_201_1","unstructured":"BaronM.Amylin withdraws application for Symlin in Europe. MarketWatch.2022; Accessed December 7 2023.https:\/\/www.marketwatch.com\/story\/amylin\u2010withdraws\u2010application\u2010for\u2010symlin\u2010in\u2010europe"},{"key":"e_1_2_17_202_1","doi-asserted-by":"publisher","DOI":"10.1002\/pdi.2300"},{"key":"e_1_2_17_203_1","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2004.76"},{"key":"e_1_2_17_204_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.13427"},{"key":"e_1_2_17_205_1","unstructured":"SkarbalieneJ JustR.Anti\u2010diabetic effects of novel long\u2010acting amylin analogues ZP4982 and ZP5461 in ZDF rats. American Diabetes Association's (ADA) 76th Scientific Sessions (Online). Published online 2046. Accessed December 7 2023.https:\/\/static1.squarespace.com\/static\/58983777d1758e28995640b4\/t\/5d4953643b48f80001ed9c5a\/1565086566205\/Jolanta+Skarbaliene+ADA+poster+Anti\u2010diabetic+effects+of+novel+long\u2010acting+amylin+analogues.pdf"},{"key":"e_1_2_17_206_1","unstructured":"AdisInsight.ZP 4982.2023Accessed December 7 2023.https:\/\/adisinsight.springer.com\/drugs\/800045554"},{"key":"e_1_2_17_207_1","unstructured":"Boehringer Ingelheim.Evaluation of Safety and Tolerability of Single Rising Doses of BI 473494 in Healthy Subjects.2022Accessed December 7 2023.clinicaltrials.gov.https:\/\/clinicaltrials.gov\/study\/NCT03195088?tab=results"},{"key":"e_1_2_17_208_1","unstructured":"TaylorP.Boehringer shows its hand in obesity. PharmaPhorum.2023;10: Accessed December 7 2023.https:\/\/pharmaphorum.com\/news\/boehringer\u2010shows\u2010its\u2010hand\u2010obesity"},{"key":"e_1_2_17_209_1","unstructured":"BI 473494.AdisInsight.2018Accessed December 7 2023.https:\/\/adisinsight.springer.com\/drugs\/800049758"},{"key":"e_1_2_17_210_1","unstructured":"Zaeland Pharma.Zealand pharma regains worldwide rights to amylin analog program from Boehringer Ingelheim. GlobalNewswire.2020; Accessed December 7 2023.https:\/\/www.globenewswire.com\/news\u2010release\/2020\/03\/20\/2004337\/0\/en\/Zealand\u2010Pharma\u2010regains\u2010worldwide\u2010rights\u2010to\u2010Amylin\u2010analog\u2010program\u2010from\u2010Boehringer\u2010Ingelheim.html"},{"key":"e_1_2_17_211_1","unstructured":"Zealand Pharma.Shaping the future management of obesity. Zealand Pharma Obesity R&D Event.2023Accessed December 9 2023.https:\/\/www.zealandpharma.com\/wp\u2010content\/uploads\/2023\/12\/Zealand\u2010Pharma\u2010Obesity\u2010RD\u2010Event\u20105\u2010Dec\u201023.pdf"},{"key":"e_1_2_17_212_1","doi-asserted-by":"crossref","unstructured":"OlsenMB H\u00f6velmannU GriffinJ et\u00a0al.92\u2010LB: safety tolerability and clinical effects of ZP8396 a novel long\u2010acting amylin analog\u2014a single ascending dose trial. Diabetes.2023;72(Supplement_1).https:\/\/www.zealandpharma.com\/media\/eb1azc1d\/zp8396\u2010phase1\u2010mad\u2010part\u20101\u2010obesityweek\u20102023.pdf","DOI":"10.2337\/db23-92-LB"},{"key":"e_1_2_17_213_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00514.2015"},{"key":"e_1_2_17_214_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.119.263392"},{"key":"e_1_2_17_215_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10102365"},{"key":"e_1_2_17_216_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.119.263723"},{"key":"e_1_2_17_217_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101282"},{"key":"e_1_2_17_218_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.119.257576"},{"key":"e_1_2_17_219_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175837"},{"key":"e_1_2_17_220_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14921"},{"key":"e_1_2_17_221_1","unstructured":"KeyBioscienceAG.Clinical trial results: a double\u2010blind placebo\u2010controlled randomized study to evaluate the efficacy and safety of KBP\u2010042 in patients with type 2 diabetes. EU Clinical Trials Register.2019; Accessed December 7 2023.https:\/\/www.clinicaltrialsregister.eu\/ctr\u2010search\/trial\/2017\u2010001061\u201024\/results"},{"key":"e_1_2_17_222_1","unstructured":"KeyBioscienceAG.A Clinical Study to Evaluate the Safety Tolerability PK PD and Efficacy of KBP\u2010089 in Patients With T2DM.2020Accessed December 7 2023.clinicaltrials.gov.https:\/\/clinicaltrials.gov\/study\/NCT03907202"},{"key":"e_1_2_17_223_1","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab048.108"},{"key":"e_1_2_17_224_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01751-7"},{"key":"e_1_2_17_225_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01163-7"},{"key":"e_1_2_17_226_1","unstructured":"Novo Nordisk A\/S.A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight (REDEFINE 1).2023Accessed December 7 2023.clinicaltrials.gov.https:\/\/clinicaltrials.gov\/study\/NCT05567796"},{"key":"e_1_2_17_227_1","unstructured":"Novo Nordisk A\/S.A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight (REDEFINE 2).2023Accessed December 7 2023.clinicaltrials.gov.https:\/\/clinicaltrials.gov\/study\/NCT05394519"},{"key":"e_1_2_17_228_1","unstructured":"Novo Nordisk A\/S.A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight (REDEFINE 6).2023Accessed December 7 2023.clinicaltrials.gov.https:\/\/clinicaltrials.gov\/study\/NCT05996848"},{"key":"e_1_2_17_229_1","unstructured":"Novo Nordisk A\/S.A Research Study to See How Well CagriSema Compared to Semaglutide Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor (REIMAGINE 2).2023Accessed December 7 2023.clinicaltrials.gov.https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT06065540"},{"key":"e_1_2_17_230_1","unstructured":"Novo Nordisk A\/S.A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight.2023Accessed December 7 2023.clinicaltrials.gov.https:\/\/clinicaltrials.gov\/study\/NCT06131437"},{"key":"e_1_2_17_231_1","unstructured":"Eli Lilly and Company.FDA Approves Lilly's Zepbound\u2122 (tirzepatide) for Chronic Weight Management a Powerful New Option for the Treatment of Obesity or Overweight with Weight\u2010Related Medical Problems.2023Accessed December 7 2023.https:\/\/investor.lilly.com\/news\u2010releases\/news\u2010release\u2010details\/fda\u2010approves\u2010lillys\u2010zepboundtm\u2010tirzepatide\u2010chronic\u2010weight"}],"container-title":["Pharmacology Research &amp; Perspectives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.1243","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T23:31:00Z","timestamp":1723764660000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/prp2.1243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,17]]},"references-count":230,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1002\/prp2.1243"],"URL":"https:\/\/doi.org\/10.1002\/prp2.1243","archive":["Portico"],"relation":{},"ISSN":["2052-1707","2052-1707"],"issn-type":[{"value":"2052-1707","type":"print"},{"value":"2052-1707","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,17]]},"assertion":[{"value":"2023-12-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e1243"}}